Literature DB >> 8859775

Altered mucin core peptide immunoreactivity in the colon polyp-carcinoma sequence.

S B Ho1, S L Ewing, C K Montgomery, Y S Kim.   

Abstract

Altered mucin glycosylation occurs in colonic adenomas and can correlate with risk for malignant transformation. The purpose of this study was to determine if immunoreactivity of core tandem repeat peptides of specific mucin genes correlates with histopathologic criteria of malignant potential in the colon. Expression of MUC1, MUC2, and MUC3 core tandem repeat proteins was examined in specimens of normal mucosa (n = 20), hyperplastic polyps (n = 10), adenomatous polyps (n = 89), and invasive cancer (n = 19). An immunohistochemical scoring system that takes into account specimen heterogeneity and yields an integrated numerical score subject to statistical analysis was used. RNA message levels from tubular and tubulovillous adenomas (n = 13), normal colon (n = 12), and moderately differentiated adenocarcinomas (n = 8) were determined using RNA slot blot analysis with mucin-specific cDNA probes. MUC1 staining was rarely present in normal colon. MUC2 immunoreactivity was limited to goblet cells in most normal colonic crypts, and MUC3 staining was weakly expressed in the upper crypt regions only. In comparison with normal and hyperplastic specimens, MUC1 and MUC3 immunoreactivity scores were significantly increased in adenomas of increasing villous histology, size, and dysplasia. MUC2 scores were significantly increased in adenomas of greater villous histology and size. Comparable MUC1, MUC2, and MUC3 mRNA levels were present in adenomas and normal colon, whereas mucin mRNA levels were decreased in adenocarcinomas. We conclude that enhanced immunoreactivity of MUC1, MUC2 and MUC3 mucin tandem repeats occurs in adenomatous polyps and is associated with an increased risk for malignant transformation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8859775

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  16 in total

Review 1.  Mucins and mucosal protection in the gastrointestinal tract: new prospects for mucins in the pathology of gastrointestinal disease.

Authors:  A P Corfield; N Myerscough; R Longman; P Sylvester; S Arul; M Pignatelli
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

2.  Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer.

Authors:  Ann Willman Silk; Robert E Schoen; Douglas M Potter; Olivera J Finn
Journal:  Mol Immunol       Date:  2009-02-13       Impact factor: 4.407

3.  Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair status.

Authors:  A Lugli; I Zlobec; K Baker; P Minoo; L Tornillo; L Terracciano; J R Jass
Journal:  J Clin Pathol       Date:  2006-06-30       Impact factor: 3.411

4.  Immunodiscrimination of colorectal neoplasia using MUC1 antibodies: discrepant findings in tissue versus stool.

Authors:  P J Limburg; D A Ahlquist; J A Gilbert; J J Harrington; G G Klee; P C Roche
Journal:  Dig Dis Sci       Date:  2000-03       Impact factor: 3.199

5.  MUC1 and MUC2 mucins in flat and polypoid colorectal adenomas.

Authors:  Y Ajioka; H Watanabe; J R Jass
Journal:  J Clin Pathol       Date:  1997-05       Impact factor: 3.411

6.  Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer.

Authors:  Shiv Ram Krishn; Sukhwinder Kaur; Lynette M Smith; Sonny L Johansson; Maneesh Jain; Asish Patel; Shailendra K Gautam; Michael A Hollingsworth; Ulla Mandel; Henrik Clausen; Wing-Cheong Lo; Wai-Tong Louis Fan; Upender Manne; Surinder K Batra
Journal:  Cancer Lett       Date:  2016-02-16       Impact factor: 8.679

7.  Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer.

Authors:  Pamela L Beatty; Sowmya Narayanan; Jean Gariépy; Sarangarajan Ranganathan; Olivera J Finn
Journal:  Cancer Prev Res (Phila)       Date:  2010-03-23

8.  Inflammation driven by overexpression of the hypoglycosylated abnormal mucin 1 (MUC1) links inflammatory bowel disease and pancreatitis.

Authors:  Deepak K Kadayakkara; Pamela L Beatty; Michael S Turner; Jelena M Janjic; Eric T Ahrens; Olivera J Finn
Journal:  Pancreas       Date:  2010-05       Impact factor: 3.327

9.  MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.

Authors:  Takashi Kimura; John R McKolanis; Lynda A Dzubinski; Kazi Islam; Douglas M Potter; Andres M Salazar; Robert E Schoen; Olivera J Finn
Journal:  Cancer Prev Res (Phila)       Date:  2012-12-17

Review 10.  Cancer immunoprevention.

Authors:  Olivera J Finn; Pamela L Beatty
Journal:  Curr Opin Immunol       Date:  2016-01-19       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.